Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 June 2016
Arimoclomol for treating Niemann-Pick disease Type C [ID1312]Status:In developmentProgramme:Highly specialised technologies guidanceExpected publication date: TBC
Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA694)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 April 2021
Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238)Product type:GuidanceProgramme:NICE guidelinePublished: 14 December 2023
Cardiovascular risk assessment and lipid modification (QS100)Product type:Quality standardLast updated: 24 May 2023Published: 4 September 2015
Cardiovascular risk assessment and lipid modificationStatus:In developmentExpected publication date: 23 July 2025
Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over (TA1002)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 September 2024
Evinacumab for treating homozygous familial hypercholesterolemia in children aged 5 to 11 TS ID 11806Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 June 2016
Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 February 2016
Familial hypercholesterolaemia (QS41)Product type:Quality standardLast updated: 2 November 2017Published: 13 August 2013
Familial hypercholesterolaemia: identification and management (CG71)Product type:GuidanceProgramme:Clinical guidelineLast updated: 4 October 2019Published: 27 August 2008
Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides (TA805)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 July 2022
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA733)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 6 October 2021
Metreleptin for treating lipodystrophy (HST14)Product type:GuidanceProgramme:Highly specialised technologies guidancePublished: 24 February 2021
Obicetrapib or obicetrapib–ezetimibe for treating primary heterozygous hypercholesterolaemia or mixed dyslipidaemia TS ID 12103Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Olipudase alfa for treating Niemann-Pick disease types A and B [ID3913 ]Status:In developmentProgramme:Highly specialised technologies guidanceExpected publication date: TBC
Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal) (TA961)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 March 2024
Sebelipase alfa for treating Wolman disease (HST30)Product type:GuidanceProgramme:Highly specialised technologies guidancePublished: 10 January 2024
Venglustat for treating gangliosidoses in people 2 years and over ID 6358Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
VTS-270 for treating Niemann-Pick type C1 [ID1267]Status:In developmentProgramme:Highly specialised technologies guidanceExpected publication date: TBC